Literature DB >> 18032585

Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells.

Anush Oganesian1, Lucas C Armstrong, Mary M Migliorini, Dudley K Strickland, Paul Bornstein.   

Abstract

TSPs 1 and 2 function as endogenous inhibitors of angiogenesis. Although thrombospondins (TSPs) have been shown to induce apoptosis in HMVECs, we reasoned that a homeostatic mechanism would also be needed to inhibit EC growth without causing cell death, e.g., in the maintenance of a normal vascular endothelium. HMVECs, cultured in low serum, responded to VEGF with an increase in [(3)H]thymidine incorporation that was inhibited by TSPs and was accompanied by decreases in the phosphorylation of Akt and MAPK, without an increase in apoptosis. RAP, an inhibitor of the low-density lipoprotein (LDL) family of endocytic receptors, and blocking antibodies to VLDLR were as effective as TSPs in the inhibition of thymidine uptake in response to VEGF, and the effects of these agents were not additive. Supportive evidence for the role of the VLDLR in mediating this inhibition was provided by the demonstration of a high-affinity interaction between TSPs and the VLDLR. We propose that TSP1 and TSP2, together with the VLDLR, initiate a nonapoptotic pathway for maintenance of the normal adult vascular endothelium in a quiescent state, similar to that invoked for the regulation of mitogenesis by PDGF, but involving signaling via the VLDLR rather than LRP1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032585      PMCID: PMC2230579          DOI: 10.1091/mbc.e07-07-0649

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  54 in total

1.  Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells.

Authors:  N Guo; H C Krutzsch; J K Inman; D D Roberts
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein.

Authors:  I Mikhailenko; D Krylov; K M Argraves; D D Roberts; G Liau; D K Strickland
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

3.  Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway.

Authors:  J E Nör; R S Mitra; M M Sutorik; D J Mooney; V P Castle; P J Polverini
Journal:  J Vasc Res       Date:  2000 May-Jun       Impact factor: 1.934

4.  39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.

Authors:  J Herz; J L Goldstein; D K Strickland; Y K Ho; M S Brown
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

5.  The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein.

Authors:  R Simantov; M Febbraio; R L Silverstein
Journal:  Matrix Biol       Date:  2004-12-30       Impact factor: 11.583

6.  Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis.

Authors:  K Gupta; P Gupta; R Wild; S Ramakrishnan; R P Hebbel
Journal:  Angiogenesis       Date:  1999       Impact factor: 9.596

7.  The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes.

Authors:  K M Argraves; F D Battey; C D MacCalman; K R McCrae; M Gåfvels; K F Kozarsky; D A Chappell; J F Strauss; D K Strickland
Journal:  J Biol Chem       Date:  1995-11-03       Impact factor: 5.157

8.  Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.

Authors:  Xuefeng Zhang; Eric Galardi; Mark Duquette; Jack Lawler; Sareh Parangi
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

9.  Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor.

Authors:  P K Frykman; M S Brown; T Yamamoto; J L Goldstein; J Herz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

10.  CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.

Authors:  D W Dawson; S F Pearce; R Zhong; R L Silverstein; W A Frazier; N P Bouck
Journal:  J Cell Biol       Date:  1997-08-11       Impact factor: 10.539

View more
  35 in total

Review 1.  Lipoprotein receptors--an evolutionarily ancient multifunctional receptor family.

Authors:  Marco Dieckmann; Martin Frederik Dietrich; Joachim Herz
Journal:  Biol Chem       Date:  2010-11       Impact factor: 3.915

Review 2.  Thrombospondins in the transition from myocardial infarction to heart failure.

Authors:  Jonathan A Kirk; Oscar H Cingolani
Journal:  J Mol Cell Cardiol       Date:  2015-12-10       Impact factor: 5.000

3.  Expanding functions of lipoprotein receptors.

Authors:  Joachim Herz; Ying Chen; Irene Masiulis; Li Zhou
Journal:  J Lipid Res       Date:  2008-11-17       Impact factor: 5.922

Review 4.  Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.

Authors:  Patrick R Lawler; Jack Lawler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

Review 5.  Thrombospondin-1 in ocular surface health and disease.

Authors:  William Foulsham; Thomas H Dohlman; Sharad K Mittal; Yukako Taketani; Rohan Bir Singh; Sharmila Masli; Reza Dana
Journal:  Ocul Surf       Date:  2019-06-05       Impact factor: 5.033

6.  miR-200c regulates FGFR-dependent epithelial proliferation via Vldlr during submandibular gland branching morphogenesis.

Authors:  Ivan T Rebustini; Toru Hayashi; Andrew D Reynolds; Melvin L Dillard; Ellen M Carpenter; Matthew P Hoffman
Journal:  Development       Date:  2011-11-24       Impact factor: 6.868

7.  Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.

Authors:  Eldrid Borgan; Evita M Lindholm; Siver Moestue; Gunhild M Mælandsmo; Ole Christian Lingjærde; Ingrid S Gribbestad; Anne-Lise Børresen-Dale; Olav Engebraaten; Therese Sørlie
Journal:  Mol Oncol       Date:  2012-10-23       Impact factor: 6.603

8.  Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis.

Authors:  Marie M Krady; Jianmin Zeng; Jun Yu; Susan MacLauchlan; Eleni A Skokos; Weiming Tian; Paul Bornstein; William C Sessa; Themis R Kyriakides
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

9.  The role of thrombospondins in wound healing, ischemia, and the foreign body reaction.

Authors:  Themis R Kyriakides; Susan Maclauchlan
Journal:  J Cell Commun Signal       Date:  2009-10-21       Impact factor: 5.782

10.  Thrombospondins function as regulators of angiogenesis.

Authors:  Paul Bornstein
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.